Business, Health Care, Local News

Opdivo® (nivolumab) in combination with CABOMETYX® (cabozantinib) demonstrates significant survival benefits in patients with advanced Renal Cell Carcinoma in pivotal Phase 3 CheckMate -9ER trial

Opdivo in combination with CABOMETYX showed superior overall survival and doubled median progression-free survival and objective response rate with a favorable safety profile vs. sunitinib Efficacy benefits were observed across key patient subgroups, including all International Metastatic Renal Cell Carcinoma Database Consortium

Business, Health Care, Local News

CURE® Speaking Out video series supports Blood Cancer Awareness Month and World Lymphoma Awareness Day

Susan M. O’Brien, M.D., one of the nation’s foremost leukemia experts, discusses the future of frontline therapies and upcoming clinical trials associated with chronic lymphocytic leukemia. CRANBURY, N.J.–(BUSINESS WIRE)–#BloodCancerAwarenessMonth–In support of Blood Cancer Awareness Month and World Lymphoma Awareness Day, the CURE®

Business, Local News

Dodge Momentum Index inches up in August

HAMILTON, N.J.–(BUSINESS WIRE)–The Dodge Momentum Index increased 1.8% in August to 126.5 (2000=1000) from the revised July reading of 124.2. The Momentum Index, issued by Dodge Data & Analytics, is a monthly measure of the first (or initial) report for nonresidential building